# Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure

> **NCT06340048** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **HELP Therapeutics Co., Ltd.** · enrollment: 36 (estimated)

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** HiCM-188 therapy

## Key facts

- **NCT ID:** NCT06340048
- **Lead sponsor:** HELP Therapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-09-05
- **Primary completion:** 2026-11-10
- **Final completion:** 2027-05-10
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-02-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06340048

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06340048, "Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06340048. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*